Ligelizumab lacks the ability to cross-link FcεRIα-bound IgE-Fc3-4 fragments and it will be interesting to see whether it shows a reduced risk of anaphylaxis and an altered safety profile as compared to omalizumab. Here, FCER1A is linked to anaphylaxis.